MRI Dye
Generic Name:
Gadoxetate disodium, gadopentetate, gadobenate dimeglumine, gadodiamide, gadoversetamide, gadoteridol
MRI Dye Description:
MRI (Magnetic Resonance Imaging) Dye, commonly referred to as MRI contrast agent or paramagnetic agent, is a gadolinium-based product marketed by various pharmaceutical companies. However, the overall results of the dye are the same when used in conjunction with a MRI scan. MRI Dye is a liquid consisting of a chelating agent and paramagnetic ion. While the paramagnetic ion used in most MRI Dyes is gadolinium, the chelating agent used by the manufacturer of MRI Dye differs.
MRI Dye is injected into the body intravenously prior to an MRI scan. The dye is strongly attracted to the magnetic forces in MRI scans, resulting in an enhanced “image” of the area of the body being scanned (as opposed to a scan without the MRI Dye). The amount of MRI Dye injected into a patient is typically determined by body weight and the body part being tested.
MRI Dye Uses:
MRI Dye is not a drug used to treat any disease. It is used as an aid in the diagnostics of diseases and conditions in the body.
Central Nervous System (CNS) conditions that are diagnosed with MRI Dye(Magnevist, MultiHance, Omniscan, Optimark, and ProHance) in conjunction with a MRI scan include:
- Lesions in the brain or the appearance of abnormal vascularity in the blood-brain barrier (a protective network of blood vessels and cells acting as filtering mechanisms for the blood directed towards the brain); or
- Lesions with abnormal vascularity in the spine, as well as in associated tissues of both the brain and the spine.
Other body conditions that are diagnosed via the use of MRI Dye (Magnevist, MultiHance, Omniscan, and ProHance) in conjunction with a MRI scan include:
- Lesions of abnormal vascularity within thoracic space (the chest cavity area between the neck and the diaphragm that is encased by the ribs and is noncardiac);
- Lesions of the pelvic cavity (the space bounded by the bones in the pelvis and pelvic girdle); or
- Lesions of the retroperitoneal space (the space behind the peritoneum, a serous membrane that lines the cavity of the abdomen).
Liver conditions that are diagnosed via the use of MRI Dye (Optimark, Eovist) in conjunction with a MRI scan include lesions due to suspected focal liver disease in adults.
Extracranial/extraspinal tissue conditions that are diagnosed via the use of MRI Dye (Magnevist) in conjunction with a MRI scan include lesions of abnormal vascularity in the area of the head and neck.
MRI Dye Dosage Information:
Typical Dosage Recommendation:
MRI Dye is a liquid administered intravenously to the patient prior to the MRI scan. Factors such as age, weight and type of scan being performed dictate the dosage amount.
The recommended dose of MRI Dye for a MRI scan is typically 0.2 mL/kg of body weight. Following the administration of the MRI Dye, a 5 mL flush consisting of 0.9% of sodium chloride can be injected to ensure that the desired volume of contrast agent has been administered.
The imaging procedure should be performed within 1 hour of the initial MRI Dye injection. Additional dosage may be administered within 30 minutes of the initial dosage. Additional dosage volumes are determined by the specific need of a particular image, where reference to the product’s dosage chart is required.
Overdosing:
Overdoses of MRI Dyes have not been reported.
MRI Dye FDA Approval:
The five U.S.-approved gadolinium MRI Dyes were approved between 1988 and 2004.
MRI Dye Recall/Black Box Warning Information:
The U.S. Food and Drug Administration ordered gadolinium-based MRI Dyes to add a heightened warning label to state that patients with kidney insufficiency who receive gadolinium-based agents are at risk for developing a debilitating, potentially fatal disease known as nephrogenic systemic fibrosis (NSF). Risk also exists for patients just before or just after liver transplantation, or those with chronic liver disease. Omniscan was the most commonly reported agent associated with the development of NSF, followed by Magnevist and Optimark.
-
May 9, 2011, 1:27 pm
-
May 6, 2011, 1:37 pm
-
May 5, 2011, 12:55 pm
-
May 4, 2011, 1:29 pm
